An observational study in Angio Edema, sponsored by University Hospital, Lille. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by University Hospital, Lille · Observational
The unpredictable nature of the attacks is one of the essential characteristics of bradykinin angioedema. The two main difficulties for physicians managing a patient with bradykinin angioedema are to make the diagnosis and anticipate the severity.
Biomarkers can be used to diagnose, guide treatment, or predict the severity of a disease. However, the identification of biomarkers is currently difficult in bradykinin both for diagnosis and prognosis. While measurement of C4 and C1 inhibitor (quantitative and functional assays) allows the diagnosis of bradykinin angioedema due to C1 inhibitor deficiency, whether genetic or acquired, many patients with normal C1 inhibitor bradykinin angioedema, either hereditary or acquired, are still difficult to diagnose. For patients with hereditary angioedema with C1-inhibitor deficiency, there is no biomarker currently available to predict the severity. Any biomarker that could improve the diagnosis on the one hand, and improve the prediction of the frequency and severity of the response to treatment on the other hand, would obviously be extremely useful. The aim of our study is to assess the existence possible biomarkers for diagnosis and prognosis of bradykinin angioedema.
69 studies on the registry are indexed under Angioedema; 16 are open to participants now.
This study's enrollment of 1 is below the median of 181 across 19 observational studies indexed under Angioedema.
Browse Angioedema studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with bradykinin angioedema or histamine-mediated angioedema followed in internal medicine department of Lille University Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 2 : Patients with histamine-mediated angioedema
Exclusion Criteria:
Other: Biobanking
Other: Biobanking
For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
Also known as: Biobanking without genetic analysis
compare measurement by proteomics of proteins differentially expressed in the plasma by ANOVA t test
to evaluate the contribution of a plasma proteomic signature including albumin, gammaglobulin and alpha macroglobulin the plasma proteome of two group: Enrollment (for group 1 and group 2) + 1 year visit (for group 1 only)
Time frame: through study completion an average of 1 year
analyze the following biomarkers for diagnostic purposes in both groups.
analyze the following biomarkers for diagnostic purposes: C1 inhibitor quantity
Time frame: Enrollment (for group 1 and group 2) + 1 year visit (for group 1 only)
the value of plasma proteome markers and the markers mentioned above as predictors of the occurrence of attacks
Time frame: at 1 year
Implementation of a biobank to identify future biomarkers
Time frame: Enrollment (for group 1 and group 2) + 1 year visit (for group 1 only)
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.